These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12471654)

  • 21. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of abciximab in the treatment of coronary artery disease.
    Gabriel HM; Oliveira EI
    Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
    Hudson MP; Greenbaum AB; Harrington RA; Ohman EM
    J Thromb Thrombolysis; 1999 Jun; 7(3):241-5. PubMed ID: 10373717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
    Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
    Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.
    Desch S; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Pauschinger M; Kerber S; Kleinertz K; de Waha S; Eitel I; Schuler G; Thiele H
    J Am Coll Cardiol; 2013 Sep; 62(13):1214-5. PubMed ID: 23850911
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Störk T; Fröhlich E; Möckel M
    Lancet; 2001 Dec; 358(9297):1996-7. PubMed ID: 11747950
    [No Abstract]   [Full Text] [Related]  

  • 30. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS.
    Cohen M
    Lancet; 2001 Jun; 357(9272):1899-900. PubMed ID: 11425405
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of early administration of abciximab in acute ST-segment elevation myocardial infarction in the emergency room.
    Arhan A; Ecollan P; Madonna-Py B; Kergueno J; Bennaceur M; Josse MO; Montalescot G; Riou B
    Presse Med; 2006 Jan; 35(1 Pt 1):45-50. PubMed ID: 16462663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 33. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring platelet GP IIb/IIIa antagonist therapy.
    Coller BS
    Circulation; 1998 Jan 6-13; 97(1):5-9. PubMed ID: 9443422
    [No Abstract]   [Full Text] [Related]  

  • 36. Recovery of coronary flow and left ventricular function after abciximab.
    Mak KH; Neumann FJ; Blasini MR; Schmitt MC; Alt ME; Dirschinger MJ; Gawaz MM; Kastrati MA; Schömig MA
    Circulation; 1999 Nov; 100(22):e110. PubMed ID: 10578011
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
    Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ
    Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
    J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    Tcheng JE; Campbell ME
    J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
    Califf RM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.